Amgen's DeLLphi-305 trial shows survival gains for Imdelltra in small cell lung cancer
Amgen says DeLLphi-305 showed significant overall and progression-free survival benefits for Imdelltra with Imfinzi in first-line maintenance, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, which cites an AI-generated summary, the DeLLphi-305 study showed significant overall and progression-free survival benefits for Imdelltra combined with Imfinzi in first-line maintenance treatment. Responses were observed across patient subgroups, and the reported toxicities were described as manageable.
The development program is now moving into earlier small cell lung cancer settings. Monitoring and dosing initiatives are also underway, which the source says are intended to widen patient access to the therapy.
why it matters
Oncology drugs remain a key growth driver for large pharmaceutical companies, so these results matter for Amgen investors. Expanding Imdelltra into earlier lines of treatment could enlarge the drug's potential market, though the financial impact is not disclosed in the text.
market impact
Amgen: Imdelltra data may support expectations for growth in the oncology portfolio
tags
instruments
sources
- AMGN: DeLLphi-305 delivered strong first-line maintenance survival results, accelerating IMDELLTRA’s SCLC expansion plans — TradingView, 24 October 2026 at 21:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗